[1] The WHO World Mental Health Survey Consortium. Prevalence, severity, and unmet need for treatment of mental disorders in the World Health Organization World Mental Health Surveys. JAMA, 2004; 291, 2581−90. doi:  10.1001/jama.291.21.2581
[2] Alexopoulos GS. Depression in the elderly. Lancet, 2005; 365, 1961−70. doi:  10.1016/S0140-6736(05)66665-2
[3] Otte C, Gold SM, Penninx BW, et al. Major depressive disorder. Nat Rev Dis Primers, 2016; 2, 16065. doi:  10.1038/nrdp.2016.65
[4] Asarnow JR, Porta G, Spirito A, et al. Suicide attempts and nonsuicidal self-injury in the treatment of resistant depression in adolescents: findings from the TORDIA study. J Am Acad Child Adolesc Psychiatry, 2011; 50, 772−81. doi:  10.1016/j.jaac.2011.04.003
[5] Choi KW, Stein MB, Nishimi KM, et al. An exposure-wide and Mendelian randomization approach to identifying modifiable factors for the prevention of depression. Am J Psychiatry, 2020; 177, 944−54. doi:  10.1176/appi.ajp.2020.19111158
[6] Campbell D, Green MJ, Davies N, et al. Effects of depression on employment and social outcomes: a Mendelian randomisation study. J Epidemiol Community Health, 2022; 76, 563−71. doi:  10.1136/jech-2021-218074
[7] Plante DT. The evolving nexus of sleep and depression. Am J Psychiatry, 2021; 178, 896−902. doi:  10.1176/appi.ajp.2021.21080821
[8] de Ornelas Maia ACC, de Azevedo Braga A, Paes F, et al. Comorbidity of depression and anxiety: association with poor quality of life in type 1 and 2 diabetic patients. Clin Pract Epidemiol Ment Health, 2013; 9, 136−41. doi:  10.2174/1745017901309010136
[9] Wang HQ, Wang ZZ, Chen NH. The receptor hypothesis and the pathogenesis of depression: genetic bases and biological correlates. Pharmacol Res, 2021; 167, 105542. doi:  10.1016/j.phrs.2021.105542
[10] Pierce BL, Burgess S. Efficient design for Mendelian randomization studies: subsample and 2-sample instrumental variable estimators. Am J Epidemiol, 2013; 178, 1177−84. doi:  10.1093/aje/kwt084
[11] Wishart DS, Knox C, Guo AC, et al. DrugBank: a comprehensive resource for in silico drug discovery and exploration. Nucleic Acids Res, 2006; 34, D668−72. doi:  10.1093/nar/gkj067
[12] Hemani G, Zheng J, Elsworth B, et al. The MR-Base platform supports systematic causal inference across the human phenome. eLife, 2018; 7, e34408. doi:  10.7554/eLife.34408
[13] Howard DM, Adams MJ, Shirali M, et al. Genome-wide association study of depression phenotypes in UK Biobank identifies variants in excitatory synaptic pathways. Nat Commun, 2018; 9, 1470. doi:  10.1038/s41467-018-03819-3
[14] Wray NR, Ripke S, Mattheisen M, et al. Genome-wide association analyses identify 44 risk variants and refine the genetic architecture of major depression. Nat Genet, 2018; 50, 668−81. doi:  10.1038/s41588-018-0090-3
[15] Cross-Disorder Group of the Psychiatric Genomics Consortium. Identification of risk loci with shared effects on five major psychiatric disorders: a genome-wide analysis. Lancet, 2013; 381, 1371−9. doi:  10.1016/S0140-6736(12)62129-1
[16] Lin ZT, Deng YQ, Pan W. Combining the strengths of inverse-variance weighting and Egger regression in Mendelian randomization using a mixture of regressions model. PLoS Genet, 2021; 17, e1009922. doi:  10.1371/journal.pgen.1009922
[17] Oliva M, Muñoz-Aguirre M, Kim-Hellmuth S, et al. The impact of sex on gene expression across human tissues. Science, 2020; 369, eaba3066. doi:  10.1126/science.aba3066
[18] van Os E, van den Broek WW, Mulder PGH, et al. Depression in patients with primary biliary cirrhosis and primary sclerosing cholangitis. J Hepatol, 2007; 46, 1099−103. doi:  10.1016/j.jhep.2007.01.036
[19] Krynicki CR, Upthegrove R, Deakin JFW, et al. The relationship between negative symptoms and depression in schizophrenia: a systematic review. Acta Psychiatr Scand, 2018; 137, 380−90. doi:  10.1111/acps.12873
[20] Bhui K, Puffet A, Herriot P. A survey of sexual problems amongst psychiatric inpatients. Soc Psychiatry Psychiatr Epidemiol, 1995; 30, 73−7. doi:  10.1007/BF00794946
[21] Lyu JC, Zhang J, Hennessy DA. Characteristics and risk factors for suicide in people with schizophrenia in comparison to those without schizophrenia. Psychiatry Res, 2021; 304, 114166. doi:  10.1016/j.psychres.2021.114166
[22] Kiriakidou M, Ching CL. Systemic lupus erythematosus. Ann Intern Med, 2020; 172, ITC81−96. doi:  10.7326/AITC202006020
[23] Parperis K, Psarelis S, Chatzittofis A, et al. Association of clinical characteristics, disease activity and health-related quality of life in SLE patients with major depressive disorder. Rheumatology, 2021; 60, 5369−78. doi:  10.1093/rheumatology/keab123
[24] Al-Homood IA, Omran NE, Alwahibi AS, et al. Depression in patients with systemic lupus erythematosus: a multicenter study. Saudi J Med Med Sci, 2017; 5, 248−53. doi:  10.4103/sjmms.sjmms_79_16
[25] Cojocaru DC, Costin M, Bădeanu LE, et al. Depression-A fellow traveler with systemic lupus erythematosus. Rev Med Chir Soc Med Nat Iasi, 2015; 119, 974−81.
[26] Gelernter J. SLC6A4 polymorphism, population genetics, and psychiatric traits. Hum Genet, 2014; 133, 459−61. doi:  10.1007/s00439-013-1412-2
[27] Booij L, Szyf M, Carballedo A, et al. DNA methylation of the serotonin transporter gene in peripheral cells and stress-related changes in hippocampal volume: a study in depressed patients and healthy controls. PLoS One, 2015; 10, e0119061. doi:  10.1371/journal.pone.0119061
[28] Iga JI, Watanabe SY, Numata S, et al. Association study of polymorphism in the serotonin transporter gene promoter, methylation profiles, and expression in patients with major depressive disorder. Hum Psychopharmacol Clin Exp, 2016; 31, 193−9. doi:  10.1002/hup.2527
[29] Okada S, Morinobu S, Fuchikami M, et al. The potential of SLC6A4 gene methylation analysis for the diagnosis and treatment of major depression. J Psychiatr Res, 2014; 53, 47−53. doi:  10.1016/j.jpsychires.2014.02.002
[30] Iosifescu DV, Jones A, O'Gorman C, et al. Efficacy and safety of AXS-05 (dextromethorphan-bupropion) in patients with major depressive disorder: a phase 3 randomized clinical trial (GEMINI). J Clin Psychiatry, 2022; 83, 21m14345.
[31] Berman RM, Cappiello A, Anand A, et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry, 2000; 47, 351−4. doi:  10.1016/S0006-3223(99)00230-9
[32] Zarate CA Jr, Singh JB, Carlson PJ, et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry, 2006; 63, 856−64. doi:  10.1001/archpsyc.63.8.856
[33] Murrough JW, Wan LB, Iacoviello B, et al. Neurocognitive effects of ketamine in treatment-resistant major depression: association with antidepressant response. Psychopharmacology, 2014; 231, 481−8. doi:  10.1007/s00213-013-3255-x
[34] Murrough JW, Iosifescu DV, Chang LC, et al. Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial. Am J Psychiatry, 2013; 170, 1134−42. doi:  10.1176/appi.ajp.2013.13030392
[35] Chandley MJ, Szebeni A, Szebeni K, et al. Elevated gene expression of glutamate receptors in noradrenergic neurons from the locus coeruleus in major depression. Int J Neuropsychopharmacol, 2014; 17, 1569−78. doi:  10.1017/S1461145714000662
[36] Myung W, Song J, Lim SW, et al. Genetic association study of individual symptoms in depression. Psychiatry Res, 2012; 198, 400−6. doi:  10.1016/j.psychres.2011.12.037
[37] Prévot T, Sibille E. Altered GABA-mediated information processing and cognitive dysfunctions in depression and other brain disorders. Mol Psychiatry, 2021; 26, 151−67. doi:  10.1038/s41380-020-0727-3
[38] Schweizer C, Balsiger S, Bluethmann H, et al. The γ2 subunit of GABAA receptors is required for maintenance of receptors at mature synapses. Mol Cell Neurosci, 2003; 24, 442−50. doi:  10.1016/S1044-7431(03)00202-1
[39] Yin HL, Pantazatos SP, Galfalvy H, et al. A pilot integrative genomics study of GABA and glutamate neurotransmitter systems in suicide, suicidal behavior, and major depressive disorder. Am J Med Genet Part B Neuropsychiatr Genet, 2016; 171, 414−26. doi:  10.1002/ajmg.b.32423